Substance P, opioid, and catecholamine systems in the mouse central nervous system (CNS).

Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol (2012) 0.84

Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet (1999) 6.09

Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med (2001) 3.17

NK1 (substance P) receptor antagonists--why are they not analgesic in humans? Trends Pharmacol Sci (2000) 2.81

Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem (1998) 2.03

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther (1999) 1.63

Neurotransmitter candidates of somatosensory primary afferent fibres. Neuroscience (1983) 1.15

Potentiated opioid analgesia in norepinephrine transporter knock-out mice. J Neurosci (2000) 1.11

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci (1999) 1.09

Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. Behav Neurosci (1997) 1.05

The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proc Natl Acad Sci U S A (2002) 1.01

5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci (2001) 1.01

Effect of intrathecally administered noradrenergic antagonists on nociception in the rat. Brain Res (1984) 0.98